URGN Investors Have the Opportunity to Lead the UroGen Pharma Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Core Viewpoint - UroGen Pharma Ltd. is facing a federal securities class action due to allegations of misleading statements regarding the effectiveness of its drug UGN-102, leading to significant stock price declines following negative FDA feedback and advisory committee decisions [4][5][6]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is investigating potential claims against UroGen and has set a deadline of July 28, 2025, for investors to seek the role of lead plaintiff in the class action [2]. - Investors who suffered losses exceeding $75,000 in UroGen between July 27, 2023, and May 15, 2025, are encouraged to contact the firm to discuss their legal options [1]. Group 2: Allegations Against UroGen - The complaint alleges that UroGen and its executives violated federal securities laws by making false or misleading statements regarding the ENVISION clinical study and its design, which lacked a concurrent control arm [4]. - The FDA expressed doubts about the effectiveness of UGN-102, stating that the trial's design made it difficult to interpret primary endpoints [5]. - UroGen's stock price fell significantly after the FDA's briefing document and the advisory committee's negative vote on the NDA for UGN-102, with a drop of 25.8% to $7.31 per share on May 16, 2025, and a further decline of 44.7% to $4.17 per share on May 21, 2025 [5][6]. Group 3: Class Action Participation - The lead plaintiff in the class action will be the investor with the largest financial interest who is also typical of class members, and any member of the class can move to serve as lead plaintiff [7]. - Participation as a lead plaintiff does not affect the ability of other class members to share in any recovery [7]. Group 4: Additional Information - Faruqi & Faruqi encourages anyone with information regarding UroGen's conduct, including whistleblowers and former employees, to contact the firm [8]. - For more information about the class action, interested parties can visit the firm's website or contact the partner directly [9].